Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA
复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

VOLUNTARY ANNOUNCEMENT

COMPLETION OF THE ISSUANCE OF THE SECOND TRANCHE SCIENTIFIC AND TECHNOLOGICAL INNOVATION BONDS FOR 2025

References are made to (i) the announcement of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "**Company**") dated 25 March 2025 in relation to, among others, the Notice of Acceptance for Registration (Zhong Shi Xie Zhu [2025] No. MTN272) issued by the Association on 20 March 2025 regarding the acceptance of the registration of the medium-term notes of the Company, with the registered amount of RMB4 billion and Effective Registration Period of two years commencing from the date of issuance of the Notice, during which medium-term notes may be issued in tranches; and (ii) the announcement of the Company dated 27 April 2025 in relation to the completion of the issuance of the first tranche of medium-term notes (scientific and technological innovation notes) for 2025 by the Company in April 2025, with a total issuance amount of RMB0.5 billion (collectively, the "**Announcements**"). Unless otherwise specified, capitalized terms used herein shall have the same meaning as ascribed to them in the Announcements.

The Company has recently completed the issuance of the second tranche of scientific and technological innovation bonds for 2025 (the "**Current Debt Financing Instruments**") within the abovementioned registered amount. The results of the issuance of Current Debt Financing Instruments are set out below:

Name of bonds	The Second Tranche of Scientific and Technological Innovation Bonds of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. for 2025* (上海復星醫藥(集團)股份有限公司2025年度第二期科技創新債券)		
Short name of bonds	25 Fosun Pharma MTN002 (Scientific and Technological Innovation Bonds)* (25復星醫藥 MTN002 (科創債))	**Code of bonds**	102583283
Aggregate principal amount	RMB1 billion	**Term**	Two years
Issue Price	RMB100 per RMB100 in principal amount	**Coupon rate**	2.70%
Value date	7 August 2025	**Payment date**	7 August 2027
Leading underwriter	China Merchants Bank Co., Ltd.		
Joint leading underwriters	Bank of Beijing Co., Ltd., Shanghai Pudong Development Bank Co., Ltd., Bank of Communications Co., Ltd.		

The relevant documents in relation to the Current Debt Financing Instruments have been published on the website of China Money at https://www.chinamoney.com.cn and the website of Shanghai Clearing House at https://www.shclearing.com.cn.

This announcement does not constitute, or form part of, an offer or invitation, or solicitation or inducement of an offer, to subscribe for or purchase the Current Debt Financing Instruments or any of other securities of the Company, nor is this announcement circulated to invite offers for any securities of the Company.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Yuqing
Chairman

Shanghai, the PRC
8 August 2025

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong and Mr. Wang Kexin; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Pan Donghui and Mr. Wu Yifang; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee Director of the Company is Ms. Yan Jia.

* *for identification purposes only*